Scott Myers

Scott Myers is the current director at Harpoon Therapeutics. Prior to their current position, Myers was with Dynavax Technologies and Qiming Venture Partners USA. From April 2021 to November 2021, they were an independent director at Trillium Therapeutics Inc.

Trillium Therapeutics Inc. was acquired by Pfizer in November of 2021. The company was formed in Ontario and named after the province’s official flower, Trillium grandiflorum. Trillium Therapeutics is an immuno-oncology company targeting CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a “don’t eat me” signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. By blocking this “don’t eat me” signal with decoy receptors, the company aims to unmask tumor cells and make them visible to the immune system. As a leading CD47-focused company, Trillium Therapeutics has two decoy receptors (TTI-621 and TTI-622) that are currently being evaluated in patients with hematological malignancies and solid tumors.

At the end of 2019, under new leadership, Trillium underwent a transformational program that included corporate reorganization, the creation of a more clinical development-centric organization and strategic re-prioritization to focus

Scott Myers received their high school diploma from Springfield High School. Scott then attended Northwestern University, where they earned a Bachelor of Arts in Biology/Biological Sciences, General. Finally, they obtained their MBA in Finance and International Business from The University of Chicago Booth School of Business.